Gain Therapeutics (GANX)

Executive Summary

Gain Therapeutics is a Swiss biotechnology company leveraging its proprietary AI and physics-based Magellan™ platform to discover novel allosteric small molecule therapies. The company focuses on high-unmet-need disorders, with its lead program GT-02287 targeting GBA-Parkinson's disease. By modulating protein function through stabilization, destabilization, or degradation, Gain aims to overcome limitations of traditional inhibition or activation therapies. Founded in 2017 and publicly traded (NASDAQ: GANX), the company has positioned itself at the intersection of computational drug discovery and precision medicine for neurodegenerative conditions.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 interim data readout for GT-02287 in GBA-Parkinson's disease55% success
• Q1 2027Potential strategic partnership or licensing deal for Magellan platform40% success
• H1 2027IND filing or advancement of second pipeline candidate targeting lysosomal storage disorder30% success